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Long-term efficacy of oral pirmenol in 
suppressing ventricular premature 
depolarizations 
Pirmenol is an investigational type 1A antiarrhythmic drug the long-term efficacy of which has not 
been fufly determined. Therefore the longterm effkacy of oral pirmenol in suppressing 
ventrkular premature dopolarixations (VPOs) was asseoased in an open-label, dose-titration study. 
Twelve patients (etQht men and four women; mean age 57 + 12 years) were treated for 24 to 36 
months (mean 33 * 4). Seven had strUctureI heart dtseaee (three valvular heart @@ease, two 
Ischemk heart disease, and two hypertensive heart disease) and five dld not. The mean left 
ventrkulsr ejectlon fraction was 0.63 + 0.13. Exclusion criteria included <3D VPOs/hr, >15 
beats of ventiicular tachycardia (VT), or prior failure of more than two antiarrhythmic drugs. Drug 
efficacy was assessed by 26hour ambulatory ECG monitoring performed every 3 months during 
the first year, every 4 months during the second year, and at &month intervals durjng the third 
year. The niean hourly frequency of VP08 during the placebo phase was 732 f  608. Seven 
patients (56%) were treatsd successfully with effective (>75%) long-term suppression of VPOs. 
Two patients (17%) had a partial response with effective suppresslon of VP08 for the first 16 
months and 5 months of treatment, respectively. Three patients failed to show condlstent 
suppresslon of VPds while receiving pirmenol. The daily dose of plrmenol ranged from 200 to 
500 mg (mean 317 -t 94 mg at the beglnning of the study and 375 + 97 mg at the end). No 
proarrhythmk effects were Identified during long-term treatment, and none of the patients 
wttiidrew from the study prematurely. Mild side effect8 included dry mouth, bad taste, and 
urinary hesitancy. We conclude that oral pirmenol maintains effective longterm suppression of 
VPDs in approximately 60% of patients and is Well tolerated during chronic administration. No 
proarrhythmic effects occurred during long-term treatment. (AM HEART J 1988; 116:379.) 
Michael de Buitleir, MD, MRCPI, Barry J. Crevey, MD, Theresa Johnson, RN, 
William H. Kou, MD, Steven D. Nelson, MD, Steven Schmaltz, MPH, 
and Fred Morady, MD. Ann Arbor, Mich. 
Pirmenol is an investigational type 1A antiarrhyth- 
mic drug that has been shown in short-term studies 
to be effective in suppressing ventricular premature 
depolarizations (VPDs).‘-lo To date only two studies 
have examined in detail the long-term efficacy of 
oral pirmenol in suppressing VPDs. Hampton et al.” 
treated 11 patients for 1 to 24 months, but only six 
patients continued treatment for more than 12 
months. Farnhams reported data on 28 patients 
who were treated for 25 months. In the present. re- 
port we describe the efficacy of oral pirmenol in sup- 
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pressing VPDs over a follow-up period of 24 to 36 
months. 
METHODS 
Patients. Men and postmenopausal women, aged 21 to 
79 years, were suitable for inclusion in this study if they 
had >30 VPDskr on a 24-hour ambulatory ECG record- 
ing during the prestudy screening period. Patients with 
multiform or repetitive VPDs or nonsustained VT were 
included, whereas patients with sustained VT were 
excluded. Nonsustained VT was defined as VT 3 to 15 
beats in duration. All patients were either asymptomatic 
or had palpitations as the only symptom of arrhythmia. 
Only patients with a left ventricular ejection fraction 
bO.30, determined by radionuclide ventriculography or 
echocardiography, were considered for inclusion in the 
study. Exclusion criteria included congestive heart failure, 
severe valvular heart disease, significantly impaired renal 
or hepatic function, second- or third-degree atrioventricu- 
lar block, atrial flutter or fibrillation, severe obstructive 
airways disease, prolonged QT syndrome, and myocardial 
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Fig. 1. VPDs/hour during treatment with placebo and pirmenol in seven patients (Nos. 1,3,4,&S, 9, and 
12) who displayed >75% long-term suppression of VPDs. 
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Months on Pirmenol 
Fig. 2. VPDs/hour during treatment with placebo and pirmenol in five patients (Nos. 2,6,7,10, and 11) 
who failed to achieve long-term suppression of VPDs. 
infarction or cardiac surgery within the previous 3 
months. 
Twelve patients (eight men and four women; mean age 
57 + 12 years [-t standard deviation]) were recruited into 
the study. Three patients had valvular heart disease, two 
had ischemic heart disease, two had hypertensive heart 
disease, and the remaining five patients had no structural 
heart disease. Mean left ventricular ejection fraction was 
0.63 2 0.13. The mean number of antiarrhythmic drugs 
that patients had been treated with before entry into the 
study was 2.5 + 1.4 (range 0 to 4); these had been 
f-JiaonntGn.v-2 L ~. _A_-_.. uCIGaLlDt: vl” either inefficacy or intolerable 
side effects. 
Study design. The study was open label in design and 
included dose titration as necessary to achieve efficacy. 
The study protocol was approved by the institutional 
review board of the University of Michigan Medical 
Center, and all patients gave written informed consent. 
The study was a continuation of a short-term, double- 
blind, randomized, placebo-controlled evaluation of oral 
pirmenol reported previously.’ The study included 
patients who had been successfully treated with pirmenol 
(>75% reduction in 24-hour VPD counts) in the short- 
term study and also those who had received placebo. 
Another patient was also included, despite a reduction in 
VPDs of only 47 % during the short-term study, because of 
a decrease in symptoms and episodes of nonsustained VT. 
The previous short-term study’ consisted of 19 consecu- 
tive patients, of whom 14 received pirmenol and five 
received placebo. Thus the present group of 12 patients 
was selected from an original population of 19 patients. 
Patients who had been successfully treated during the 
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Table 1. Long-term efficacy of pirmenol 
Mean VPDslhr by months on treatment Mean % 
Patient Placebo change us 
No. Age Sex phase 1 5 9 12 16 20 24 30 36 placebo 
1 51 M 711 (-‘9”9) (-9;) (-9:) (-9”9, (-9:) (-993 (-9:) (-‘9”9, t-9:) -99 
2 55 F 355 194 214 72 420 
(-45) (-40) (-80) (+W 
(-ii, (-ii) (2) 163 
(-54) (-968) 
-64 
3 61 M 281 (-9:) (-9:) (-9:) $3, (-ii) (2:) (-9:) (-9’9, (-9:) -97 
4 79 F 79 (-ii) (-963) (-tit) (Z9) (-945) c-9:) (-9:) (-loi) (-vi, -90 
5 70 M 1776 (-it) (-ii) (-ii) $7) (-Z) 296 284 342 166 -92 
(-83) (-84) (-81) (-91) 
6 55 M 294 (-ii) (A) (-!g $5) ,-K, 133 237 337 138 -64 
(-55) (-19) (+15) (-53) 
7 45 F 891 339 351 157 158 816 -65 
(-62) (-61) (-82) t-82) t-8) 
(-Z) (4) 597 322 
(-33) (-64) 
8 35 F 631 (-9’9, (-9:) (-9:) (-A) (-ii) t-9:) (-993 562 - -88 
(-11) - 
9 58 M 1161 216 320 134 313 249 113 161 317 - -80 
(-81) (-72) (-88) (-73) (-79) t-901 (-86) (-73) - 
10 68 M 302 (-9:) (-E) (Z) 461 556 313 162 365 - 0 
(+53) t+w (+4) t-46) (+21) - 
11 48 M 1951 779 1269 1572 698 914 1415 1349 1293 - -40 
(-60) (-35) (-19) (-64) (-53) (-27) (-31) (-36) - 
12 55 M 354 (-9:) (-2) (-9:) (-t (-9’9) -98 
Numbers in parentheses represent percentage change versus placebo. 
short-term study initially continued to receive the same 
dose of pirmenol with upward titration as necessary to 
maintain efficacy. Other patients were given an initial 
daily dose of 200 or 300 mg of pirmenol given in two 
equally divided doses. If the next 24-hour ambulatory 
ECG showed <75% suppression of VPDs, the daily dose 
was increased by 100 mg. Subsequent 100 mg increments 
in daily dose‘ were made in a similar fashion, to a 
maximum of 500 mg, provided the drug was well toler- 
ated. 
Patient evaluation. The study was conducted on an 
outpatient basis, and patients were seen at monthly 
intervals during the first year, at 2-month intervals during 
the second year, and at 3-month intervals during the third 
year of treatment. On each visit patients underwent a 
complete clinical examination and were questioned about 
the occurrence of side effects. General biochemical in- 
dexes and ECGs were checked during alternate clinic 
visits. Patients had an annual chest x-ray examination and 
an ophthalmologic examination at the end of the first 
year. 
Ambulatory ECG recordings. Twenty-four-hour ambu- 
latory ECG recordings were obtained every 3 months 
during the first year, every 4 months during the second 
year, and every 6 months during the third year. A Cardio 
Data Systems two-channel (leads 2 and V,) Avionics 
recorder was used. All tapes were read by Cardio Data 
Systems (Haddonfield, NJ) with computerized analysis. 
Pirmenol was considered to be clinically effective if there 
was more than 75% reduction in the daily frequency of 
VPDs on each 24-hour recording compared to the screen- 
ing period. This criterion for efficacy was used because 
prior studies have demonstrated its validity.‘* 
The screening period took place before patients entered 
the short-term study,’ and was not repeated before the 
long-term trial. It was 1 week in duration at the end of 
which frequency of VPDs was measured by a single 24-hour 
ambulatory ECG recording after all antiarrhythmic drugs 
had been discontinued for at least five half-lives. 
Plasma pirmenol concentraiion. A venous blood sam- 
ple was drawn for determination of trough plasma pirme- 
no1 concentration on each clinic visit. Analysis of plasma 
pirmenol concentrations was performed by Warner Lam- 
bert/Parke Davis Research Division by means of a high- 
pressure liquid chromatographic technique.13 
Patients were permitted to continue taking pirmenol 
after 3 years on a compassionate basis. During this time 
they were evaluated every 4 months, but no 24-hour 
ambulatory ECG recordings were performed. 
Statistics. Statistical comparisons were performed by 
means of repeated-measures analysis of variance to deter- 
mine time effects. Fisher’s least significant difference 
multiple-comparisons procedure was used to determine 
significant differences between individual time points. A 
mixed-model analysis of variance was used to compare 
plasma pirmenol concentrations in responders and nonre- 
sponders. An unpaired t test was used where appropriate. 
A p value of less than 0.05 was considered significant, and 
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all variables were expressed as mean k one standard 
deviation. 
RESULTS 
Efficacy of pirmenol (Table I; Figs. 1 and 2). Seven 
patients (58%) showed effective long-term suppres- 
sion of VPDs (92 % compared with placebo) during a 
mean follow-up period of 33 f 4 months (range 24 
to 36) (Fig. 1). In four of these seven patients (Nos. 
1, 3, 5, and 12) suppression of VPDs exceeded 80% 
on each of the 24-hour ambulatory ECGs. In two of 
the seven patients (Nos. 4 and 8), suppression of 
VPDs decreased to 49 % and 11% , respectively, on a 
single 24-hour recording but exceeded 85% on all 
others. The final patient (No. 9) had a mean overall 
80% suppression of VPDs, but on three individual 
ambulatory ECG recordings suppression of VPDs 
fell slightly below 75 % . 
Of the remaining five patients (Fig. 2), two (Nos. 6 
and 10) had a partial response, with effective sup- 
pression of VPDs fbr the first 16 months and 5 
months of treatment, respectively. However, patient 
No. 10 and a 4% to 84% increase in VPDs on five of 
six subsequent 24-hour ambulatory ECG recordings. 
This increase in the frequency of VPDs did not meet 
standard criteria for proarrhythmia.14 Three 
patients (25%) failed to show consistent suppres- 
sion of VPDs while receiving pirmenol. Mean sup- 
pression of VPDs among the three nonresponders 
was 50%. These patients have continued to receive 
treatment because of symptomatic improvement. 
Six of the 12 patients have completed the 36- 
month study protocol and have entered a compas- 
sionate-use phase. Five patients have completed 30 
months of treatment, and the final patient has 
completed 24 months of treatment. Of the seven 
patients who displayed effective suppression of 
VPDs during the short-term study, four maintained 
long-term suppression of VPDs. 
The mean daily dose of pirmenol at the beginning 
of the study was 317 f 94 mg and at the last visit it 
was 375 f 97 mg. Five patients continued to receive 
the same dose throughout the study, whereas in six 
patients the dose was increased. In one patient the 
onset of side effects necessitated a reduction in dose 
from 400 to 300 mg/day. The mean daily dose of 
pirmenol among the seven long-term responders was 
343 + 113 mg and among the three nonresponders, 
433 rt 58 mg; the difference was not statistically 
significant. There was no significant difference in 
left ventricular ejection fraction between responders 
(0.65 + 0.12) and nonresponders (0.60 + 0.16), and 
there was no significant difference in underlying 
heart disease between the two groups. 
Adverse effects. Pirmenol was well tolerated and 
caused only mild side effects during chronic admin- 
istration. None of the patients withdrew from the 
study because of side effects. In one patient it was 
necessary to reduce the dose of pirmenol from 400 
mg to 300 mg/day because of nausea, dizziness, 
fatigue, and a sensation of bad taste. Reduction in 
the dose resulted in resolution of the side effects. 
Overall, eight patients complained of dry mouth, 
five reported urinary hesitancy and occasional palpi- 
tations, four noted occasional dizziness or light- 
headedness, two complained of a metallic or bad 
taste and constipation, and nausea and blurring of 
vision occurred in one patient each. 
ECG findings. There was a statistically significant 
lengthening of the QT interval with active treatment 
from a mean of 0.38 + 0.03 second with placebo to 
0.42 + 0.03 second after 1 month of pirmenol (11% 
increase; p < 0.001). QT prolongation was main- 
tained during continuous treatment with pirmenol 
but never exceeded 0.42 + 0.05 second. There was 
no correlation between the degree of QT prolonga- 
tion and suppression of VPDs. There was no signif- 
icant change in the PR interval or QRS duration 
during treatment with pirmenol. 
Biochemistry and hematology. There were no signif- 
icant changes in serum potassium, creatinine, blood 
urea nitrogen, or plasma glucose levels or in liver 
function during the study. Of 10 patients who had 
serum antinuclear antibody detectable intermittent- 
ly during the study, seven had received prior treat- 
ment with procainamide. In 5 of the 10 patients 
serum antinuclear antibody had not been detectable 
before they entered the study. However, lupus-like 
syndrome did not develop in any of the patients. 
Eight patients had been treated with procainamide 
before beginning treatment with pirmenol and of 
these, seven had serum antinuclear antibody detect- 
able during the study. The white cell count or 
platelet count did not change significantly in any 
patient during the study. There were no drug- 
related changes on serial chest x-ray or ophthalmo- 
logic examinations during the study. 
Plasma pirmenol concentrations. Only plasma pir- 
menol levels drawn between 10 and 14 hours of the 
dosing interval were included in the analysis. The 
mean trough plasma pirmenol concentration among 
the seven responders was 0.91 + 0.44 ,zg/ml, and 
among the three nonresponders it was 1.12 f 0.54 
pg/ml. There were no significant differences 
between the two vaiues. Within-patient variability 
in trough plasma pirmenol levels was almost as large 
as that between patients. 
Of the two patienta who displayed partial sup- 
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pression of VPDs patient No. 6 had a plasma 
pirmenol concentration of 0.86 -+ 0.41 pg/ml during 
suppression and 0.68 + 0.03 pg/ml during relapse. 
In patient No. 10, plasma pirmenol levels were 
similar during the effective suppression (1.22 +- 0.11 
pg/ml) and relapse phases (1.10 +- 0.15 pg/ml. 
DISCUSSION 
The results of this study show that oral pirmenol 
maintains effective long-term suppression of VPDs 
in a significant proportion of patients (58%) in 
whom it is used. In an additional small number of 
patients, pirmenol shows initial efficacy for a period 
of months with subsequent recurrence of VPDs. 
Pirmenol is well tolerated during long-term 
administration, and mild side effects are related 
mainly to its known anticholinergic properties. In 
our investigation, all patients who entered the study 
are still receiving pirmenol, and in only one patient 
was a reduction in dose necessary because of side 
effects. No proarrhythmic effects were noted during 
long-term administration, which contrasts with a 
possible 14 % incidence of proarrhythmia during our 
short-term study.’ Therefore, as is the case with 
other type 1A antiarrhythmic drugs, proarrhythmic 
events may be more likely to occur during the early 
weeks of treatment. 
In the present study there was no significant 
difference in the trough plasma pirmenol concentra- 
tion between responders and nonresponders. These 
data suggest that plasma pirmenol concentrations 
are unlikely to be of much value in guiding antiar- 
rhythmic therapy. In contrast to our findings, 
Hampton et al. *I found that nonresponders had a 
lower steady-state plasma pirmenol level than 
responders (1.08 + 0.52 vs 1.72 f 0.74 pg/ml), 
despite receiving a larger daily dose (447 +- 102 mg 
vs 315 + 94 mg). Farnhams found that effective 
suppression of VPDs was more frequent when the 
trough plasma pirmenol concentration was 21.6 
@g/ml. 
Two patients in our study (Nos. 6 and 10) dis- 
played initial effective suppression of VPDs with 
subsequent recurrence of VPDs despite continuing 
treatment. In patient No. 6, mean trough plasma 
pirmenol concentration during effective suppression 
of VPDs was slightly higher than that during recur- 
rence. The patient received the same dose of pirme- 
no1 during both phases. Although the difference in 
plasma levels was not statistically significant, it is 
possible that a higher plasma pirmenol concentra- 
tion during the later part of the study would have 
achieved greater suppression of VPDs. In patient 
No. 10, plasma pirmenol levels were similar during 
the effective suppression and relapse phases despite 
an increase in dose. Treatment for chronic obstruc- 
tive pulmonary disease may have increased this 
patient’s frequency of VPDs. 
The finding of an intermittently positive antinu- 
clear antibody titer in 10 of 12 patients is of interest. 
Seven of the 10 patients had been treated with 
procainamide before pirmenol. These data suggest 
that pirmenol is similar to procainamide, but nota- 
bly all patients remained asymptomatic with no 
evidence of a lupus-type reaction. Thus it appears 
that a lupus-type syndrome, if it occurs at all, may 
be rare during treatment with pirmenol. 
ECG changes consisted of a significant prolonga- 
tion (11% ) of the QT interval. In this regard, 
pirmenol is typical of other type 1A antiarrhythmic 
drugs. It is noteworthy that we found no correlation 
between suppression of VPDs and degree of QT 
prolongation. 
The present study is the first to report follow-up 
data up to 3 years for patients receiving oral pirme- 
no1 for suppression of VPDs. The majority of previ- 
ous studies have been short-term, but two have 
reported long-term results. In one study,” 5 of 11 
patients (45%) had effective long-term suppression 
of VPDs during a mean follow-up period of 21 +- 3 
months. One early responder had a later recurrence 
of VPDs, probably related to a low plasma pirmenol 
concentration. Two patients had increased frequen- 
cy of VPDs during treatment with pirmenol (124 % 
and 168% compared to the placebo phase). As in our 
study, adverse effects were mild and 9 of 10 patients 
had at least one positive antinuclear antibody titer. 
However, none of the patients had any signs or 
symptoms of a lupus-type reaction. Farnhams found 
that 87% of 75 patients treated for 17 months had 
effective suppression of VPDs (>70%). The most 
common side effect was unusual taste, but dry 
mouth, headache, dizziness, and fatigue occurred 
also. A possible proarrhythmic effect was noted in 
three patients (2 % ). 
Pirmenol compares very favorably with other type 
1A antiarrrhythmic drugs in suppressing VPDs. In 
two short-term studies quinidine was effective in 
57 % of patients in one (>80% suppression of 
VPDs)15 and in 70% of patients in the other (>7O% 
suppression of VPDs).16 However, quinidine had to 
be discontinued in 15% of patients in one study 
because of side effects.15 Procainamide is effective in 
suppressing VPDs in 65% to 76% of patients but is 
also poorly tolerated over the long term.17 
In conclusion, pirmenol is an effective drug for 
long-term suppression of VPDs and is well tolerated. 
An effective dosing regimen consists of an initial 
384 de Buitleir et al. 
daily dose of 200 mg with subsequent upward titra- 
tion guided by suppression of VPDs as determined 
by 24-hour ambulatory ECG recordings. 
We thank JoEllen Mahs and Joan Stea for excellent secretarial 
assistance. 
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